Lead Product(s): Ibogaine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: ATAI Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Investment January 24, 2020
The investment aims at developing treatment protocol for safety of patients who are taking ibogaine for treatment of opioid use disorder (OUD).